As the impact of the COVID-19 pandemic continues to unfold, each day brings to light new realizations of just how interconnected, and sometimes vulnerable, the global supply chain for medicines is.
I was pleased to address the American Association of Pharmaceutical Scientists (AAPS) on May 12 during a webinar focused on the impact of the COVID-19 pandemic on the supply of quality medicines.
To those in the pharmaceutical industry, USP may be both familiar and a little mysterious. We’re all aware that USP documentary and reference standards help ensure the quality of medicines in the United States and around the world.
This morning, USP published a proposal in the Pharmacopeial Forum (PF) on Biological Products Nomenclature.
What happens when patients who receive a trusted treatment start experiencing adverse reactions? And what can be done to help prevent it from reoccurring?
Patients, their families and health care providers alike care about the quality of their medicines. For nearly 200 years, USP has contributed to the quality of medicines by providing publicly-available standards.
Consistent quality. Greater access. They’re what patients deserve and what USP strives to ensure across the globe through the development of public quality standards.
The quality of medicine and how it’s delivered to patients is fundamental to treating illness and maintaining health. At USP, we help build a safety net across the drug industry and healthcare system to preserve the well-being of patients.